Similar articles

• Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

  Bergshoeff AS, Fraaij PL, Verweij C, van Rossum AM, Verweel G, Hartwig NG, de Groot R, Burger DM. Bergshoeff AS, et al. J Antimicrob Chemother. 2004 Dec;54(6):1152-4. doi: 10.1093/jac/dkh490. Epub 2004 Nov 10. J Antimicrob Chemother. 2004. PMID: 15537694 Clinical Trial.
• [The treatment of 12 HIV-infected children with zidovudine].

  Scherpbier HJ, Prakken AB, de Graeff-Meeder ER, van den Berg H. Scherpbier HJ, et al. Ned Tijdschr Geneeskd. 1993 Aug 7;137(32):1610-3. Ned Tijdschr Geneeskd. 1993. PMID: 8366963 Dutch.
• Didanosine (DDI) alone is now considered the first-line therapy for symptomatic children infected with the human immunodeficiency virus (HIV).

  [No authors listed] [No authors listed] J Am Osteopath Assoc. 1996 Jun;96(6):339. J Am Osteopath Assoc. 1996. PMID: 8690619 No abstract available.
• Pediatric HIV disease: new developments in treatment and prevention.

  Melvin AJ, Frenkel LM. Melvin AJ, et al. AIDS Clin Rev. 1997-1998:109-27. AIDS Clin Rev. 1997. PMID: 9305446 Review.
• A critical analysis of recent data on zidovudine therapy: use in asymptomatic HIV infection and early HIV disease, dosing and resistance issues.

  Peto TE. Peto TE. AIDS. 1990;4 Suppl 1:S187-91. AIDS. 1990. PMID: 2152565 Review. No abstract available.